A Phase 1 interventional study of GSK1278863 in Anaemia, sponsored by GlaxoSmithKline. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-09.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.
Among the 30 studies testing GSK1278863 in Anemia, this one is the 27th largest by enrollment, is one of 3 that started in 2014, is one of 10 in phase 1, and was the 10th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:
GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 76 across the 30 interventional studies. Of the 29 that completed or were terminated, 23 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 30 have an industry lead sponsor. The 3 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
35 studies in Anemia by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 35 finished, 25 (71%) have results posted.
Among the 35 studies in Anemia by GlaxoSmithKline, this one is the 32nd largest by enrollment, is one of 3 that started in 2014, is one of 14 in phase 1, and was the 15th registered.
GlaxoSmithKline’s Anemia studies by the year they started, since 2006.
1 of the studies testing GSK1278863 in Anemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07300111Phase 3Qilu Pharmaceutical Co., Ltd.A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies testing GSK1278863 in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 35 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
GSK1278863 is an orally-active, novel small molecule agent which inhibits hypoxia-inducible factor (HIF) prolyl -4- hydroxylases (PHDs) and is in development for the treatment of anaemia associated with chronic kidney disease (CKD). As the kidney represents a major site of elimination for many drugs and their metabolites, and GSK1278863 will be administered to subjects with various stages of renal disease, it is important to characterize the pharmacokinetics in this target patient population. The purpose of this study is to characterize the pharmacokinetics of GSK1278863 and its metabolites in subjects with end stage renal disease (ESRD) undergoing peritoneal dialysis. This will be a repeat-dose, open-label, parallel-group study. Approximately 30 subjects with ESRD will be enrolled in two cohorts (15 subjects in each cohort) to ensure that 6 subjects on continuous ambulatory peritoneal dialysis (CAPD) (cohort 1) and 6 subjects on automated peritoneal dialysis APD (cohort 2) complete dosing and critical assessments. GSK1278863 will be administered once daily for 14 days. Primary pharmacokinetic assessments will be made on Days 1 and 14.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
SAFETY:
EFFICACY:
OTHER:
Exclusion Criteria:
SAFETY
EFFICACY:
OTHER:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects on continuous ambulatory peritoneal dialysis (CAPD) will receive 5 mg of GSK1278863 orally, once daily for 14 days.
Drug: GSK1278863
Subjects on automated peritoneal dialysis (APD) will receive 5 mg of GSK1278863 orally, once daily for 14 days
Drug: GSK1278863
Round, biconvex, white film coated tablet containing 5 mg GSK1278863.
Area Under the Concentration-time Curve (AUC) Over the Dosing Interval (AUC[0-tau]) of GSK1278863 and Its Metabolites
Serial blood samples were collected from participants at indicated time points for Pharmacokinetic (PK) analysis of GSK1278863 and its metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531403 and GSK2531401). Geometric mean and geometric coefficient of variation has been presented for all metabolites. NA indicates data is not available. Geometric coefficient of variation could not be calculated for CAPD cohort due to small number of participants. PK Population comprised of participants in the 'All Subjects' Population for whom a PK sample was obtained and analyzed.
Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24 hours post-dose on Day 1; Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose on Day 14
AUC From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-inf]) of GSK1278863 and Its Metabolites
Serial blood samples were collected from participants at indicated time points for PK analysis of GSK1278863 and its metabolites (GSK2487818 and GSK2531398). Geometric mean and geometric coefficient of variation has been presented for all metabolites. NA indicates data is not available. Geometric coefficient of variation could not be calculated for CAPD cohort due to small number of participants.
Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24 hours post-dose on Day 1
Maximum Observed Concentration (Cmax) of GSK1278863 and Its Metabolites
Serial blood samples were collected from participants at indicated time points for PK analysis of GSK1278863 and its metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531403 and GSK2531401). Geometric mean and geometric coefficient of variation has been presented for all metabolites. NA indicates data is not available. Geometric coefficient of variation could not be calculated for CAPD cohort due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24 hours post-dose on Day 1; Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose on Day 14
Number of Participants With Non-serious Adverse Events (AEs) and Serious AEs (SAEs)
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, is a congenital anomaly/birth defect, other situations, and is associated with liver injury and impaired liver function. Analysis was performed on All Subjects Population which comprised of all enrolled participants who received at least one dose of study treatment.
Time frame: Up to Day 24
Change From Baseline in Glucose, Calcium, Chloride, Carbon-dioxide (CO2), Potassium, Sodium and Urea Levels
Blood samples were collected from participants to evaluate clinical chemistry parameters including glucose, calcium, chloride, CO2, potassium, sodium and urea. Change from Baseline in clinical chemistry parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.
Time frame: Baseline and Day 17
Change From Baseline in Albumin and Protein Levels
Blood samples were collected from participants to evaluate clinical chemistry parameters including albumin and protein. Change from Baseline in clinical chemistry parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.
Time frame: Baseline and Day 17
Change From Baseline in Direct Bilirubin, Bilirubin, Creatinine and Urate Levels
Blood samples were collected from participants to evaluate clinical chemistry parameters including direct bilirubin, bilirubin, creatinine and urate. Change from Baseline in clinical chemistry parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.
Time frame: Baseline and Day 17
Change From Baseline in Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Gamma Glutamyl Aminotransferase (GGT) Levels
Blood samples were collected from participants to evaluate clinical chemistry parameters including ALP, AST and GGT. Change from Baseline in clinical chemistry parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.
Time frame: Baseline and Day 17
Change From Baseline in Alanine Aminotransferase (ALT) and Creatinine Kinase Levels
Blood samples were collected from participants to evaluate clinical chemistry parameters including ALT and creatinine kinase. Change from Baseline in clinical chemistry parameters at Day 3, Day 7, Day 11, Day 14 and Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Baseline and Day 3, 7, 11, 14, 17
Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Levels
Blood samples were collected from participants to evaluate clinical hematology parameters including basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocytes. Change from Baseline in clinical hematology parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. NA indicates data is not available. Mean and standard deviation are presented. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.
Time frame: Baseline and Day 17
Change From Baseline in Erythrocyte and Reticulocyte Levels
Blood samples were collected from participants to evaluate clinical hematology parameters including erythrocyte and reticulocyte. Change from Baseline in clinical hematology parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. NA indicates data is not available. Mean and standard deviation are presented. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.
Time frame: Baseline and Day 17
Change From Baseline in Hematocrit Levels
Blood samples were collected from participants to evaluate clinical hematology parameters including hematocrit. Change from Baseline in clinical hematology parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.
Time frame: Baseline and Day 17
Change From Baseline in Hemoglobin Levels
Blood samples were collected from participants to evaluate clinical hematology parameters including hemoglobin. Change from Baseline in clinical hematology parameters at Day 3, Day 7, Day 11 and Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Baseline and Day 3, 7, 11, 17
Change From Baseline in Mean Corpuscular Hemoglobin Concentration (MCHC)
Blood samples were collected from participants to evaluate clinical hematology parameters including MCHC. Change from Baseline in clinical hematology parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.
Time frame: Baseline and Day 17
Change From Baseline in Mean Corpuscular Volume (MCV)
Blood samples were collected from participants to evaluate clinical hematology parameters including MCV. Change from Baseline in clinical hematology parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.
Time frame: Baseline and Day 17
Change From Baseline in Mean Corpuscular Hemoglobin (MCH) Levels
Blood samples were collected from participants to evaluate clinical hematology parameters including MCH. Change from Baseline in clinical hematology parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.
Time frame: Baseline and Day 17
Number of Participants With Abnormal Electrocardiogram (ECG) Findings
Single measurements of 12-lead ECG were obtained in supine position after at least 10 minutes of rest using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT and corrected QT (QTc) interval. Participants with abnormal ECG findings at worst-case observation Carried Forward for triplicate measurements (WOCF) post-Baseline visit are presented. Only participants with data available at WOCF visit were analyzed.
Time frame: Day 17
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Vital sign measurements including SBP and DBP were taken in a supine position after at least 5 minutes of rest. Change from Baseline in SBP and DBP at Day 17 and Day 24 (follow-up) are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Baseline, Day 17 and Day 24
Change From Baseline in Pulse Rate
Vital sign measurements including pulse rate were taken in a supine position after at least 5 minutes of rest. Change from Baseline in pulse rate at Day 17 and Day 24 (follow-up) are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Baseline, Day 17 and Day 24
Change From Baseline in Body Temperature
Vital sign measurements including body temperature were taken in a supine position after at least 5 minutes of rest. Change from Baseline in body temperature at Day 17 and Day 24 (follow-up) are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Baseline, Day 17 and Day 24
Number of Participants With Abnormal Physical Examination Findings
A complete physical examination was planned to include assessments of the head, eyes, ears, nose, throat, skin, thyroid, neurological, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes and extremities. This analysis was planned but not performed. Any significant finding was captured as an AE.
Time frame: Up to Day 17
Peritoneal Dialysis Clearance of GSK1278863 and Metabolites
Peritoneal dialysate samples for PK analysis of GSK1278863 and metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531403 and GSK2531401) were collected. Peritoneal dialysis clearance of GSK1278863 and metabolites was calculated from Day 14 dialysate excretion data as total amount of analyte excreted over 24 hours divided by plasma AUC (0-tau). Geometric mean and geometric coefficient of variation are presented. NA indicates data is not available. Geometric coefficient of variation could not be calculated due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Day 14
Terminal Phase Half-life (t 1/2) of GSK1278863 and Metabolites
Serial blood samples were collected from participants at indicated time points for PK analysis of GSK1278863 and its metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531403, GSK2531401). Geometric mean and geometric coefficient of variation have been presented for all metabolites. Geometric coefficient of variation could not be calculated for CAPD cohort due to small number of participants, which is indicated by NA. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24 hours post-dose on Day 1; Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose on Day 14
Time of Occurrence of Cmax (Tmax) of GSK1278863 and Metabolites
Serial blood samples were collected from participants at indicated time points for PK analysis of GSK1278863 and its metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531403 and GSK2531401). Median and full range have been presented for all metabolites. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24 hours post-dose on Day 1; Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose on Day 14
Accumulation Ratio of GSK1278863 and Metabolites
The observed accumulation ratio was determined to estimate the extent of accumulation for GSK1278863 and metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531403 and GSK2531401) after repeat dosing. Accumulation ratio was calculated by using AUC (0-tau) values at Day 1 and Day 14. Analysis was performed using mixed effect model fitted with day (single and repeat dose) as fixed effect and participant as random effect. Mean ratio and 90% confidence intervals have been presented.
Time frame: Day 1 and Day 14
Time Invariance Ratio of GSK1278863 and Metabolites
Time invariance ratio for GSK1278863 and metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531403 and GSK2531401) was calculated by analyzing AUC (0-inf) at Day 1 and AUC (0-tau) at Day 14. Analysis was performed using mixed effect model fitted with day (single and repeat dose) as fixed effect and participant as random effect. Mean ratio and 90% confidence intervals have been presented. NA indicates data is not available. Data could not be calculated due to insufficient data.
Time frame: Day 1 and Day 14
Plasma Concentration of Erythropoietin
Serial blood samples were collected from participants at indicated time points to analyze plasma concentration of erythropoietin after repeat-dose administration of GSK1278863. Geometric mean and geometric coefficient of variation have been presented. NA indicates data is not available. Geometric coefficient of variation could not be calculated for CAPD cohort due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Pre-dose and 4, 8 ,12, 24 hours post-dose on Day 1 and Day 14; Pre-dose on Day 3, 7, 11
Plasma Concentration of Hepcidin
Serial blood samples were collected from participants at indicated time points to analyze plasma concentration of hepcidin after repeat-dose administration of GSK1278863. Geometric mean and geometric coefficient of variation have been presented. NA indicates data is not available. Geometric coefficient of variation could not be calculated for CAPD cohort due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Pre-dose and 4, 8 ,12, 24 hours post-dose on Day 1 and Day 14; Pre-dose on Day 3, 7, 11
This repeat-dose, pharmacokinetic (PK) study of GSK1278863 was conducted at two centers in the United States (US). Participants with End Stage Renal Disease (ESRD) undergoing continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) were included in this study.
| Milestone | Participants Undergoing CAPD | Participants Undergoing APD |
|---|---|---|
| Started | 1 | 7 |
| Completed | 1 | 4 |
| Not completed | 0 | 3 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Other: reached stopping criteria | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 |
Serial blood samples were collected from participants at indicated time points for Pharmacokinetic (PK) analysis of GSK1278863 and its metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531403 and GSK2531401). Geometric mean and geometric coefficient of variation has been presented for all metabolites. NA indicates data is not available. Geometric coefficient of variation could not be calculated for CAPD cohort due to small number of participants. PK Population comprised of participants in the 'All Subjects' Population for whom a PK sample was obtained and analyzed.
| Hour into nanograms per milliliter | Participants Undergoing CAPD | Participants Undergoing APD |
|---|---|---|
| GSK1278863; Day 1; n=1, 7 | 184.9863 ± NA | 138.6511 ± 93.5 |
| GSK1278863; Day 14; n=1, 4 | 162.9366 ± NA | 131.2826 ± 78.8 |
| GSK2391220; Day 1; n=1, 7 | 245.8999 ± NA | 147.8039 ± 47.7 |
| GSK2391220; Day 14; n=1, 4 | 258.1199 ± NA | 162.0324 ± 50.7 |
| GSK2487818; Day 1; n=1, 7 | 116.2608 ± NA | 67.4130 ± 39.1 |
| GSK2487818; Day 14; n=1, 4 | 114.1857 ± NA | 59.6501 ± 51.5 |
| GSK2506102; Day 1; n=1,6 | 59.0619 ± NA | 44.8180 ± 37.8 |
| GSK2506102; Day 14; n=1, 4 | 82.9794 ± NA | 65.2188 ± 63.0 |
| GSK2531398; Day 1; n=1, 7 | 97.0339 ± NA | 63.0979 ± 45.5 |
| GSK2531398; Day 14; n=1, 4 | 97.6587 ± NA | 65.9664 ± 53.5 |
| GSK2531403; Day 1; n=1, 7 | 291.3067 ± NA | 170.4958 ± 45.5 |
| GSK2531403; Day 14; n=1, 4 | 360.2268 ± NA | 228.6081 ± 69.4 |
| GSK2531401; Day 1; n=1, 6 | 173.5919 ± NA | 104.2971 ± 48.6 |
| GSK2531401; Day 14; n=1, 4 | 242.0514 ± NA | 205.7281 ± 20.1 |
Serial blood samples were collected from participants at indicated time points for PK analysis of GSK1278863 and its metabolites (GSK2487818 and GSK2531398). Geometric mean and geometric coefficient of variation has been presented for all metabolites. NA indicates data is not available. Geometric coefficient of variation could not be calculated for CAPD cohort due to small number of participants.
| Hour into nanograms per milliliter | Participants Undergoing CAPD | Participants Undergoing APD |
|---|---|---|
| GSK1278863 | 184.9888 ± NA | 138.6860 ± 93.6 |
| GSK2487818 | 117.2111 ± NA | 68.5089 ± 39.9 |
| GSK2531398 | 104.5268 ± NA | 73.9865 ± 51.3 |
Serial blood samples were collected from participants at indicated time points for PK analysis of GSK1278863 and its metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531403 and GSK2531401). Geometric mean and geometric coefficient of variation has been presented for all metabolites. NA indicates data is not available. Geometric coefficient of variation could not be calculated for CAPD cohort due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Nanograms per milliliter | Participants Undergoing CAPD | Participants Undergoing APD |
|---|---|---|
| GSK1278863; Day 1; n= 1, 7 | 90.400 ± NA | 58.771 ± 96.7 |
| GSK1278863; Day 14; n= 1, 4 | 57.800 ± NA | 30.303 ± 104.4 |
| GSK2391220; Day 1; n= 1, 7 | 19.900 ± NA | 11.360 ± 44.3 |
| GSK2391220; Day 14; n= 1, 4 | 20.500 ± NA | 10.966 ± 33.1 |
| GSK2487818; Day 1; n= 1, 7 | 19.400 ± NA | 10.117 ± 25.7 |
| GSK2487818; Day 14; n= 1, 4 | 18.400 ± NA | 7.262 ± 40.4 |
| GSK2506102; Day 1; n= 1, 7 | 3.820 ± NA | 2.553 ± 42.7 |
| GSK2506102; Day 14; n= 1, 4 | 5.050 ± NA | 3.590 ± 46.5 |
| GSK2531398; Day 1; n= 1, 7 | 9.300 ± NA | 5.370 ± 44.2 |
| GSK2531398; Day 14; n= 1, 4 | 9.220 ± NA | 4.857 ± 35.6 |
| GSK2531403; Day 1; n= 1, 7 | 18.600 ± NA | 11.186 ± 36.7 |
| GSK2531403; Day 14; n= 1, 4 | 23.400 ± NA | 13.267 ± 48.2 |
| GSK2531401; Day 1; n= 1, 7 | 9.920 ± NA | 4.715 ± 78.4 |
| GSK2531401; Day 14; n= 1, 4 | 13.300 ± NA | 10.404 ± 17.4 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, is a congenital anomaly/birth defect, other situations, and is associated with liver injury and impaired liver function. Analysis was performed on All Subjects Population which comprised of all enrolled participants who received at least one dose of study treatment.
| Participants | Participants Undergoing CAPD | Participants Undergoing APD |
|---|---|---|
| Non-serious AEs | 1 | 5 |
| SAEs | 0 | 0 |
Blood samples were collected from participants to evaluate clinical chemistry parameters including glucose, calcium, chloride, CO2, potassium, sodium and urea. Change from Baseline in clinical chemistry parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.
| Millimoles per liter | Participants Undergoing CAPD | Participants Undergoing APD |
|---|---|---|
| Glucose | -0.10 ± NA | 0.27 ± 7.191 |
| Calcium | 0.360 ± NA | 0.040 ± 0.2026 |
| Chloride | -2.0 ± NA | -1.3 ± 2.99 |
| CO2 | 0.0 ± NA | 0.3 ± 5.19 |
| Potassium | 0.20 ± NA | -0.45 ± 0.580 |
| Sodium | 2.0 ± NA | -1.5 ± 3.70 |
| Urea | 12.50 ± NA | -0.38 ± 3.568 |
Blood samples were collected from participants to evaluate clinical chemistry parameters including albumin and protein. Change from Baseline in clinical chemistry parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.
| Gram per liter (g/L) | Participants Undergoing CAPD | Participants Undergoing APD |
|---|---|---|
| Albumin | 3.0 ± NA | -1.3 ± 3.20 |
| Protein | 5.0 ± NA | -2.0 ± 5.48 |
Blood samples were collected from participants to evaluate clinical chemistry parameters including direct bilirubin, bilirubin, creatinine and urate. Change from Baseline in clinical chemistry parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.
| Micromoles per liter | Participants Undergoing CAPD | Participants Undergoing APD |
|---|---|---|
| Direct bilirubin | 0.0 ± NA | -0.5 ± 1.91 |
| Bilirubin | -2.0 ± NA | 0.5 ± 1.00 |
| Creatinine | 13.30 ± NA | -119.12 ± 312.679 |
| Urate | -30.0 ± NA | -25.0 ± 87.37 |
Blood samples were collected from participants to evaluate clinical chemistry parameters including ALP, AST and GGT. Change from Baseline in clinical chemistry parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.
| International unit per liter (IU/L) | Participants Undergoing CAPD | Participants Undergoing APD |
|---|---|---|
| ALP | 5.0 ± NA | -0.5 ± 16.52 |
| AST | -1.0 ± NA | -3.3 ± 3.77 |
| GGT | 0.0 ± NA | -6.3 ± 8.77 |
Blood samples were collected from participants to evaluate clinical chemistry parameters including ALT and creatinine kinase. Change from Baseline in clinical chemistry parameters at Day 3, Day 7, Day 11, Day 14 and Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| IU/L | Participants Undergoing CAPD | Participants Undergoing APD |
|---|---|---|
| ALT; Day 3; n= 1, 6 | -3.0 ± NA | -0.7 ± 3.98 |
| ALT; Day 7; n= 1, 4 | -7.0 ± NA | -2.5 ± 5.32 |
| ALT; Day 11; 1, 4 | -9.0 ± NA | -3.5 ± 5.80 |
| ALT; Day 14; n= 1, 4 | -7.0 ± NA | -0.8 ± 3.86 |
| ALT; Day 17; n= 1, 4 | -7.0 ± NA | -1.0 ± 6.06 |
| Creatine kinase; Day 3; n= 1, 6 | -12.0 ± NA | -99.7 ± 161.17 |
| Creatine kinase; Day 7; n= 1, 4 | -12.0 ± NA | -137.8 ± 230.33 |
| Creatine kinase; Day 11; n= 1, 4 | 1.0 ± NA | -135.8 ± 273.85 |
| Creatine kinase; Day 14; n= 1, 4 | 9.0 ± NA | -183.5 ± 247.13 |
| Creatine kinase; Day 17; n= 1, 4 | -2.0 ± NA | -201.5 ± 191.83 |
Blood samples were collected from participants to evaluate clinical hematology parameters including basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocytes. Change from Baseline in clinical hematology parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. NA indicates data is not available. Mean and standard deviation are presented. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.
| 10^9 cells/liter | Participants Undergoing CAPD | Participants Undergoing APD |
|---|---|---|
| Basophils | -0.020 ± NA | 0.010 ± 0.0200 |
| Eosinophils | -0.010 ± NA | 0.060 ± 0.0804 |
| Lymphocytes | 0.260 ± NA | -0.138 ± 0.3974 |
| Monocytes | 0.230 ± NA | 0.060 ± 0.3389 |
| Neutrophils | 1.350 ± NA | -0.365 ± 1.1957 |
| Platelets | 42.0 ± NA | -21.0 ± 35.92 |
| Leukocytes | 1.80 ± NA | -0.35 ± 1.008 |
Blood samples were collected from participants to evaluate clinical hematology parameters including erythrocyte and reticulocyte. Change from Baseline in clinical hematology parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. NA indicates data is not available. Mean and standard deviation are presented. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.
| 10^12 cells/liter | Participants Undergoing CAPD | Participants Undergoing APD |
|---|---|---|
| Erythrocytes | 0.00 ± NA | -0.05 ± 0.412 |
| Reticulocytes | 0.02840 ± NA | -0.00165 ± 0.044431 |
Blood samples were collected from participants to evaluate clinical hematology parameters including hematocrit. Change from Baseline in clinical hematology parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.
| Proportion of red blood cells in blood | Participants Undergoing CAPD | Participants Undergoing APD |
|---|---|---|
| Change From Baseline in Hematocrit Levels | 0.0070 ± NA | -0.0100 ± 0.03880 |
Blood samples were collected from participants to evaluate clinical hematology parameters including hemoglobin. Change from Baseline in clinical hematology parameters at Day 3, Day 7, Day 11 and Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| g/L | Participants Undergoing CAPD | Participants Undergoing APD |
|---|---|---|
| Day 3; n= 1, 7 | 7.0 ± NA | 3.1 ± 11.96 |
| Day 7; n= 1, 5 | 4.0 ± NA | -2.2 ± 9.78 |
| Day 11; n= 1, 5 | 0.0 ± NA | -3.2 ± 8.14 |
| Day 17; n= 1, 4 | 5.0 ± NA | -1.3 ± 13.74 |
Blood samples were collected from participants to evaluate clinical hematology parameters including MCHC. Change from Baseline in clinical hematology parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.
| g/L | Participants Undergoing CAPD | Participants Undergoing APD |
|---|---|---|
| Change From Baseline in Mean Corpuscular Hemoglobin Concentration (MCHC) | 8.0 ± NA | 6.3 ± 3.86 |
Blood samples were collected from participants to evaluate clinical hematology parameters including MCV. Change from Baseline in clinical hematology parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.
| Femtoliter | Participants Undergoing CAPD | Participants Undergoing APD |
|---|---|---|
| Change From Baseline in Mean Corpuscular Volume (MCV) | 1.0 ± NA | -1.5 ± 1.73 |
Blood samples were collected from participants to evaluate clinical hematology parameters including MCH. Change from Baseline in clinical hematology parameters at Day 17 are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only participants with data available at the specified time point were analyzed.
| Picograms | Participants Undergoing CAPD | Participants Undergoing APD |
|---|---|---|
| Change From Baseline in Mean Corpuscular Hemoglobin (MCH) Levels | 1.00 ± NA | -0.02 ± 0.866 |
Single measurements of 12-lead ECG were obtained in supine position after at least 10 minutes of rest using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT and corrected QT (QTc) interval. Participants with abnormal ECG findings at worst-case observation Carried Forward for triplicate measurements (WOCF) post-Baseline visit are presented. Only participants with data available at WOCF visit were analyzed.
| Participants | Participants Undergoing CAPD | Participants Undergoing APD |
|---|---|---|
| Number of Participants With Abnormal Electrocardiogram (ECG) Findings | 0 | 3 |
Vital sign measurements including SBP and DBP were taken in a supine position after at least 5 minutes of rest. Change from Baseline in SBP and DBP at Day 17 and Day 24 (follow-up) are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Millimeters of mercury | Participants Undergoing CAPD | Participants Undergoing APD |
|---|---|---|
| SBP; Day 17; n= 1, 5 | 12.0 ± NA | -10.4 ± 10.06 |
| SBP; follow-up; n= 1, 7 | 24.0 ± NA | -10.0 ± 12.46 |
| DBP; Day 17; n= 1, 5 | 10.0 ± NA | -3.4 ± 13.07 |
| DBP; follow-up; n= 1, 7 | -4.0 ± NA | 0.1 ± 12.52 |
Vital sign measurements including pulse rate were taken in a supine position after at least 5 minutes of rest. Change from Baseline in pulse rate at Day 17 and Day 24 (follow-up) are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Beats per minute | Participants Undergoing CAPD | Participants Undergoing APD |
|---|---|---|
| Day 17; n= 1, 5 | -9.0 ± NA | -5.6 ± 9.53 |
| Follow-up; n= 1, 7 | -6.0 ± NA | -7.0 ± 11.58 |
Vital sign measurements including body temperature were taken in a supine position after at least 5 minutes of rest. Change from Baseline in body temperature at Day 17 and Day 24 (follow-up) are presented. Day-1 was considered as Baseline value. Change from Baseline was calculated as post-randomization values minus Baseline value. Mean and standard deviation are presented. NA indicates data is not available. Standard deviation could not be calculated for CAPD cohort due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Degree celsius | Participants Undergoing CAPD | Participants Undergoing APD |
|---|---|---|
| Day 17; n= 1, 5 | -0.10 ± NA | -0.20 ± 0.648 |
| Follow-up; n= 1, 7 | -0.90 ± NA | -0.30 ± 0.548 |
A complete physical examination was planned to include assessments of the head, eyes, ears, nose, throat, skin, thyroid, neurological, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes and extremities. This analysis was planned but not performed. Any significant finding was captured as an AE.
No measurements were reported for this outcome.
Peritoneal dialysate samples for PK analysis of GSK1278863 and metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531403 and GSK2531401) were collected. Peritoneal dialysis clearance of GSK1278863 and metabolites was calculated from Day 14 dialysate excretion data as total amount of analyte excreted over 24 hours divided by plasma AUC (0-tau). Geometric mean and geometric coefficient of variation are presented. NA indicates data is not available. Geometric coefficient of variation could not be calculated due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Milliliter per hour | Participants Undergoing CAPD | Participants Undergoing APD |
|---|---|---|
| GSK1278863; n= 1, 0 | 12.07 ± NA | — |
| GSK2391220; n= 1, 4 | 154.68 ± NA | 31.68 ± 165.5 |
| GSK2487818; n= 1, 3 | 124.40 ± NA | 13.08 ± 195.3 |
| GSK2506102; n= 1, 4 | 167.89 ± NA | 40.05 ± 169.7 |
| GSK2531398; n= 1, 4 | 151.29 ± NA | 28.39 ± 177.5 |
| GSK2531403; n= 1, 4 | 155.75 ± NA | 36.18 ± 183.2 |
| GSK2531401; n= 1, 4 | 201.80 ± NA | 48.89 ± 199.7 |
Serial blood samples were collected from participants at indicated time points for PK analysis of GSK1278863 and its metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531403, GSK2531401). Geometric mean and geometric coefficient of variation have been presented for all metabolites. Geometric coefficient of variation could not be calculated for CAPD cohort due to small number of participants, which is indicated by NA. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Hours | Participants Undergoing CAPD | Participants Undergoing APD |
|---|---|---|
| GSK1278863; Day 1; n= 1, 7 | 1.6256 ± NA | 1.9870 ± 25.8 |
| GSK1278863; Day 14; n= 1, 4 | 1.8088 ± NA | 2.5312 ± 35.7 |
| GSK2391220; Day 14; n= 1, 4 | 9.2225 ± NA | 10.2882 ± 27.2 |
| GSK2487818; Day 1; n=1, 7 | 3.6560 ± NA | 3.3612 ± 22.7 |
| GSK2487818; Day 14; n= 1, 4 | 2.9958 ± NA | 3.8955 ± 25.3 |
| GSK2506102; Day 14; n= 1,4 | 16.2000 ± NA | 17.7692 ± 65.4 |
| GSK2531398; Day 1; n=1, 7 | 5.7900 ± NA | 7.0659 ± 35.9 |
| GSK2531398; Day 14; n= 1, 4 | 5.8275 ± NA | 7.3088 ± 40.0 |
| GSK2531403; Day 14; n= 1, 4 | 13.0606 ± NA | 14.5877 ± 43.5 |
| GSK2531401; Day 14; n= 1, 4 | 20.7794 ± NA | 26.9981 ± 54.2 |
Serial blood samples were collected from participants at indicated time points for PK analysis of GSK1278863 and its metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531403 and GSK2531401). Median and full range have been presented for all metabolites. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Hour | Participants Undergoing CAPD | Participants Undergoing APD |
|---|---|---|
| GSK1278863; Day 1; n=1, 7 | 0.50 (0.5 to 0.5) | 1.00 (1.0 to 3.0) |
| GSK1278863; Day 14; n= 1, 4 | 2.00 (2.0 to 2.0) | 2.00 (1.0 to 4.0) |
| GSK2391220; Day 1; n= 1, 7 | 3.00 (3.0 to 3.0) | 4.00 (3.0 to 8.0) |
| GSK2391220; Day 14; n= 1, 4 | 4.00 (4.0 to 4.0) | 5.00 (4.0 to 6.0) |
| GSK2487818; Day 1; n= 1, 7 | 3.00 (3.0 to 3.0) | 4.00 (2.0 to 6.0) |
| GSK2487818; Day 14; n= 1, 4 | 3.00 (3.0 to 3.0) | 4.00 (3.0 to 4.0) |
| GSK2506102; Day 1; n=1, 7 | 4.00 (4.0 to 4.0) | 8.00 (3.0 to 12.0) |
| GSK2506102; Day 14; n= 1, 4 | 4.00 (4.0 to 4.0) | 5.00 (4.0 to 6.0) |
| GSK2531398; Day 1; n= 1,7 | 4.00 (4.0 to 4.0) | 4.00 (3.0 to 8.0) |
| GSK2531398; Day 14; n= 1, 4 | 4.00 (4.0 to 4.0) | 5.00 (4.0 to 6.0) |
| GSK2531403; Day 1; n= 1, 7 | 6.00 (6.0 to 6.0) | 6.00 (2.0 to 8.0) |
| GSK2531403; Day 14; n= 1, 4 | 4.00 (4.0 to 4.0) | 6.00 (4.0 to 6.0) |
| GSK2531401; Day 1; n= 1, 7 | 8.00 (8.0 to 8.0) | 8.00 (3.0 to 12.0) |
| GSK2531401; Day 14; n= 1, 4 | 8.00 (8.0 to 8.0) | 9.00 (6.0 to 12.0) |
The observed accumulation ratio was determined to estimate the extent of accumulation for GSK1278863 and metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531403 and GSK2531401) after repeat dosing. Accumulation ratio was calculated by using AUC (0-tau) values at Day 1 and Day 14. Analysis was performed using mixed effect model fitted with day (single and repeat dose) as fixed effect and participant as random effect. Mean ratio and 90% confidence intervals have been presented.
| Ratio of AUC | All Participants |
|---|---|
| GSK1278863 | 0.896 (0.645 to 1.244) |
| GSK2391220 | 1.176 (1.043 to 1.326) |
| GSK2487818 | 1.019 (0.944 to 1.100) |
| GSK2506102 | 1.581 (1.200 to 2.081) |
| GSK2531398 | 1.116 (1.015 to 1.228) |
| GSK2531403 | 1.415 (1.131 to 1.771) |
| GSK2531401 | 1.948 (1.301 to 2.918) |
Time invariance ratio for GSK1278863 and metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531403 and GSK2531401) was calculated by analyzing AUC (0-inf) at Day 1 and AUC (0-tau) at Day 14. Analysis was performed using mixed effect model fitted with day (single and repeat dose) as fixed effect and participant as random effect. Mean ratio and 90% confidence intervals have been presented. NA indicates data is not available. Data could not be calculated due to insufficient data.
| Ratio of AUC | All Participants |
|---|---|
| GSK1278863; n= 8 | 0.896 (0.645 to 1.244) |
| GSK2487818; n= 8 | 1.007 (0.932 to 1.087) |
| GSK2531398; n= 8 | 0.986 (0.941 to 1.033) |
Serial blood samples were collected from participants at indicated time points to analyze plasma concentration of erythropoietin after repeat-dose administration of GSK1278863. Geometric mean and geometric coefficient of variation have been presented. NA indicates data is not available. Geometric coefficient of variation could not be calculated for CAPD cohort due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| IU/L | Participants Undergoing CAPD | Participants Undergoing APD |
|---|---|---|
| Day 1; pre-dose; n= 1, 7 | 13.860 ± NA | 11.363 ± 124.9 |
| Day 1; 4 hours; n= 1, 7 | 11.590 ± NA | 14.494 ± 127.1 |
| Day 1; 8 hours; n= 1, 7 | 23.540 ± NA | 36.257 ± 96.0 |
| Day 1; 12 hours; n= 1, 7 | 32.210 ± NA | 32.629 ± 112.4 |
| Day 1; 24 hours; n= 1, 7 | 13.570 ± NA | 13.005 ± 127.5 |
| Day 3; pre-dose; n= 1, 6 | 10.030 ± NA | 15.452 ± 152.9 |
| Day 7; pre-dose; n= 1, 3 | 5.070 ± NA | 8.023 ± 66.4 |
| Day 11; pre-dose; n= 1, 3 | 8.690 ± NA | 9.466 ± 69.8 |
| Day 14; pre-dose; n= 1, 4 | 9.490 ± NA | 6.036 ± 71.2 |
| Day 14; 4 hours; n= 1, 3 | 12.660 ± NA | 7.674 ± 34.9 |
| Day 14; 8 hours; n= 1, 4 | 30.220 ± NA | 19.313 ± 81.6 |
| Day 14; 12 hours; n= 1, 4 | 21.050 ± NA | 25.745 ± 74.6 |
| Day 14; 24 hours; n= 1, 4 | 6.590 ± NA | 6.735 ± 88.1 |
Serial blood samples were collected from participants at indicated time points to analyze plasma concentration of hepcidin after repeat-dose administration of GSK1278863. Geometric mean and geometric coefficient of variation have been presented. NA indicates data is not available. Geometric coefficient of variation could not be calculated for CAPD cohort due to small number of participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Micrograms per liter | Participants Undergoing CAPD | Participants Undergoing APD |
|---|---|---|
| Day 1; pre-dose; n= 1, 7 | 1143.00 ± NA | 863.21 ± 100.3 |
| Day 1; 4 hours; n= 1, 7 | 1286.00 ± NA | 922.86 ± 108.3 |
| Day 1; 8 hours; n= 1, 7 | 1427.10 ± NA | 760.14 ± 80.1 |
| Day 1; 12 hours; n= 1, 7 | 1318.00 ± NA | 812.62 ± 86.1 |
| Day 1; 24 hours; n= 1, 7 | 867.20 ± NA | 802.06 ± 93.5 |
| Day 3; pre-dose; n= 1, 6 | 1021.70 ± NA | 819.17 ± 90.7 |
| Day 7; pre-dose; n= 1, 4 | 825.30 ± NA | 839.42 ± 81.5 |
| Day 11; pre-dose; n= 1, 4 | 852.90 ± NA | 800.77 ± 91.3 |
| Day 14; pre-dose; n= 1, 4 | 734.30 ± NA | 768.33 ± 86.8 |
| Day 14; 4 hours; n= 1, 4 | 847.90 ± NA | 782.59 ± 81.9 |
| Day 14; 8 hours; n= 1, 4 | 809.90 ± NA | 738.96 ± 79.2 |
| Day 14; 12 hours; n= 1, 4 | 705.70 ± NA | 757.72 ± 87.9 |
| Day 14; 24 hours; n= 1, 4 | 801.30 ± NA | 733.66 ± 81.9 |
Collected over SAEs and non-SAEs are presented from the start of study treatment up to Day 24. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Participants Undergoing CAPD | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Participants Undergoing APD | 0/7 (0%) | 0/7 (0%) | 5/7 (71.4%) |
| Event | Participants Undergoing CAPD | Participants Undergoing APD |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/1 | 1/7 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/1 | 1/7 |
| Neck painMusculoskeletal and connective tissue disorders | 1/1 | 0/7 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/1 | 2/7 |
| NauseaGastrointestinal disorders | 0/1 | 1/7 |
| VomitingGastrointestinal disorders | 0/1 | 1/7 |
| Face oedemaGeneral disorders | 0/1 | 1/7 |
| FatigueGeneral disorders | 0/1 | 1/7 |
| PyrexiaGeneral disorders | 0/1 | 1/7 |
| InfluenzaInfections and infestations | 0/1 | 1/7 |
| Age, Continuous(Years) | Participants Undergoing CAPD | Participants Undergoing APD | Total |
|---|---|---|---|
| Mean | 44.0 ± NA | 57.4 ± 12.01 | 55.8 ± 12.09 |
| Sex: Female, Male(Participants) | Participants Undergoing CAPD | Participants Undergoing APD | Total |
|---|---|---|---|
| Female | 0 | 2 | 2 |
| Male | 1 | 5 | 6 |
| Race/Ethnicity, Customized(Participants) | Participants Undergoing CAPD | Participants Undergoing APD | Total |
|---|---|---|---|
| Race customized — American Indian or Alaska Native Heritage | 0 | 1 | 1 |
| Race customized — Black or African American Heritage | 0 | 3 | 3 |
| Race customized — White- White/Caucasian/European Heritage | 1 | 3 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2014 to primary completion in May 2017, 30 months.
Results were first posted in Mar 2019, 1 year 10 months after primary completion.
Of 34 industry-sponsored phase 1 interventional studies under Anemia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 30. This study's 30 months is above that.
Counting every sponsor, half of 48 studies reached it within 12 months; a quarter within 3 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GSK1278863